NCT01005849TerminatedPhase 4
A Parallel, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Probiotic Formula in the Prevention of Traveler's Diarrhea
Lallemand SAS1 site in 1 country420 target enrollmentStarted: October 1, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Terminated
- Sponsor
- Enrollment
- 420
- Locations
- 1
- Primary Endpoint
- Occurence of traveler's diarrhea
Study Overview
Brief Summary
The present study is designed to evaluate the effect of a mixture of probiotics on the prevention of traveler's diarrhea (TD) in subjects who travel to a country with a high risk for developing TD. Subjects will be asked to take one capsule containing a mixture of probiotics or a placebo capsule a day, within the week before departure, during the travel and up to 3 days after return. They will note the following outcomes in a diary: occurence of diarrhea, number and consistency of stools, duration of the diarrhea, presence of diarrhea-related symptoms and need for rescue medication.
The present study will examine if the use of the probiotics capsule reduces the occurence of traveler's diarrhea as compared to the placebo capsule.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male and female subjects aged 18 or over. Upper age limit set by subject's ability to participate in the study;
- •Subject must give written informed consent;
- •Plan to travel to a geographic area with high risk of TD with a travel duration between 12 and 14 days;
- •Subjects must be willing to refrain from using anti-diarrheal medications or antibiotics during the study period, unless they become clinically indicated in which case a rescue regimen can be administered;
- •Subjects willing to refrain from eating yoghurt and taking other probiotics during the study;
- •Female subjects of child-bearing potential must agree to use adequate birth control during the study period. This will be defined as hormonal contraception or a double barrier-method.
Exclusion Criteria
- •Subjects who have been previously treated with PROTECFLOR® or who have participated in previous Lallemand-sponsored studies;
- •Subjects who have been born in a developing country.
- •Subjects with a history of substance or alcohol abuse or any other psychological condition that may, in the investigator's opinion, adversely affect their co-operation with the study;
- •Subjects who receive a cholera vaccine
- •Subjects with chronic diarrhea;
- •Subjects with chronic disease such as irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) or ulcerative colitis (UC) ;
- •Subjects with gastrointestinal (GI) surgery during the last 3 months;
- •Subjects who took systemic antibiotic 15 days or less prior to the study;
- •Subjects with immunodeficiency's or immune suppression;
- •Subjects being treated for cancer with radiotherapy and/or chemotherapy;
- •Subjects with organ transplants;
- •Subjects treated with immunosuppressant drugs;
- •Subjects receiving another probiotic preparations or having received probiotic preparations within the last 15 days;
- •Subjects with tube feeding, ileostomy and colostomy;
- •Subjects diagnosed Clostridium difficile colitis within the last 3 months;
- •Women who are pregnant, or who will not consent to using adequate birth control during the study period;
- •Women who are breastfeeding.
Outcomes
Primary Outcomes
Occurence of traveler's diarrhea
Time Frame: 3 weeks
Secondary Outcomes
- Number and consistency of stools (normal, soft or unformed)(3 weeks)
- Duration of traveler's diarrhea if occurred (# days)(3 weeks)
- Presence of symptoms associated with TD (cramps, nausea, fever, blood in the stools, vomiting, bloating, flatulence, visceral pain)(3 weeks)
- Need for rescue medication(3 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
The Efficacy of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy ChildrenAcute Upper Respiratory Tract Infections (Common Cold)NCT02640352Probi AB550
Completed
Not Applicable
Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the ElderlySARS CoV-2 InfectionElderlyNCT04756466Biosearch S.A.201
Completed
Not Applicable
Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young PatientsDermatitis, AtopicNCT02585986Biopolis S.L.51
Completed
Not Applicable
The Efficacy on Overweight With Oral Supplemenation of Probiotics and PrebioticsOverweightNCT05710055Shenzhen Precision Health Food Technology Co. Ltd.,200
Completed
Not Applicable
Effect of Consuming a Combination of Probiotic Strains and a Combination of Plant Extracts and a Probiotic Strain on the Production and Nutritional Composition of Breast MilkBreast Milk ExpressionNCT04639232Biosearch S.A.58